Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Steven Chen.
Connection Strength

3.311
  1. Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy. Br J Dermatol. 2022 Mar 15.
    View in: PubMed
    Score: 0.248
  2. Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. Eur J Cancer. 2022 Mar 05; 166:21-23.
    View in: PubMed
    Score: 0.248
  3. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J Am Acad Dermatol. 2022 Feb 19.
    View in: PubMed
    Score: 0.247
  4. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. Eur J Cancer. 2021 12; 159:34-37.
    View in: PubMed
    Score: 0.242
  5. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.239
  6. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatol. 2021 05 01; 157(5):577-582.
    View in: PubMed
    Score: 0.234
  7. Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions". J Am Acad Dermatol. 2021 08; 85(2):e111-e112.
    View in: PubMed
    Score: 0.233
  8. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.232
  9. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 01; 142:143-146.
    View in: PubMed
    Score: 0.225
  10. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. J Am Acad Dermatol. 2020 Nov; 83(5):1475-1477.
    View in: PubMed
    Score: 0.216
  11. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.211
  12. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.211
  13. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020 04; 82(4):994-996.
    View in: PubMed
    Score: 0.209
  14. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746.
    View in: PubMed
    Score: 0.207
  15. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2022 03; 86(3):563-572.
    View in: PubMed
    Score: 0.058
  16. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.